MedTrace Logo

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

NCT00458367 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5296

Last updated 2010-10-18

No results posted yet for this study

Summary

The purpose of this research study is to gather information on the safety and efficacy of risperidone when used in routine clinical practice.

Conditions

Interventions

DRUG

Open label risperidone long acting injectable

intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutica N.V. Clinical Trial · Janssen Pharmaceutica N.V.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2006-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00458367 on ClinicalTrials.gov